• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kintara Therapeutics, Inc. - Common Stock (NQ:KTRA)

0.2154 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kintara Therapeutics, Inc. - Common Stock

News headline image
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
August 19, 2024
Via ACCESSWIRE
News headline image
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
July 08, 2024
Via ACCESSWIRE
News headline image
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
July 01, 2024
Via ACCESSWIRE
News headline image
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
June 03, 2024
Via ACCESSWIRE
News headline image
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA
April 05, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
KTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to Shareholders
April 03, 2024
From Halper Sadeh LLC
Via Business Wire
News headline image
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
April 03, 2024
Via ACCESSWIRE
News headline image
Is Kintara Therapeutics A Hidden Gem?
December 30, 2022
Kintara Therapeutics' earnings are in the red but impressive FDA approvals could satisfy an extreme upside potential to bring them solvent by next year. 
Via MarketBeat
News headline image
Kintara Therapeutics (NASDAQ: KTRA) Granted Orphan Drug Status for VAL-083 and the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
December 15, 2022
Kintara Therapeutics, Inc. (NASDAQ: KTRA) is engaged as a biopharmaceutical company, which is focused on the research and development of 
Via Spotlight Growth
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
December 01, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug... 
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap